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Abstract
Immunoglobulin gamma (IgG) heavy chain genes are associated with suscepti-
bility to multiple sclerosis (MS) and IgG levels in the cerebrospinal fluid (CSF).
However, how these variants are implicated in disease mechanisms remains
unknown. Here, we show that proliferating plasmablasts expressing the G1m1
allotype of IgG1 are selectively enriched in CSF of G1m1/G1m3 heterozygous
MS patients, whereas plasmablasts expressing either G1m1 or G1m3 are evenly
distributed in blood. Moreover, there was a preferential intrathecal synthesis of
oligoclonal IgG1 of the G1m1 allotype in heterozygous patients, whereas con-
trols with Lyme neuroborreliosis displayed oligoclonal IgG1 of both allotypes.
This points to a disease-specific mechanism involved in B-cell establishment
within the central nervous system in MS.
Introduction
The strong therapeutic effect of B-cell depletion shows
that these cells play an essential role in multiple sclerosis
(MS).1 B cells may contribute to disease in several ways,
including antigen presentation, cytokine secretion, and
antibody production.2 Intrathecal production of immuno-
globulin G (IgG), which was demonstrated for more than
half a century ago,3 is considered a hallmark of the dis-
ease and can be visualized as oligoclonal bands (OCBs)
by electrophoresis or isoelectric focusing of cerebrospinal
fluid (CSF) in most patients.4
Genetic markers of the IgG heavy chain genes known
to be determinants of Gm allotype polymorphisms have
recently been shown to be associated with intrathecal
levels of IgG,5–7 age at onset,6 and disease risk.7 The
intrathecal humoral immune response in MS is domi-
nated by the IgG1 subclass,8 and an early study showed
an increased G1m1 to G1m3 ratio of IgG1 in the CSF of
G1m1/G1m3 heterozygous MS patients.9 However, it
remains unknown whether this observation is due to a
preferential synthesis of IgG1 of the G1m1 allotype, or if
it can be explained by an increased turnover of IgG1 of
the G1m3 allotype under inflammatory conditions.
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Here, we demonstrate that proliferating plasmablasts
expressing the G1m1 allotype of IgG1 are selectively
enriched in the CSF of G1m1/G1m3 heterozygous MS
patients. Furthermore, a vast majority of MS patients dis-
played IgG1 OCBs of the G1m1 allotype only, whereas OCBs
of both allotypes were present in heterozygous controls with
Lyme neuroborreliosis. These results suggest that the G1m1
allotype is involved in establishment of B-cell clones within
the central nervous system (CNS) of MS patients, and opens
up for more selective B-cell depletion in a subgroup of
patients, where B cells carrying G1m1 are removed while
leaving B cells carrying all other isotypes and allotypes intact.
Methods
Patients
For flow cytometry, patients with relapsing remitting MS
(n = 25) or primary progressive MS (n = 4) were recruited
at the Departments of Neurology at Akershus University
Hospital and Oslo University Hospital. Nine patients had
not received immunomodulatory treatment at inclusion,
and the remaining received different treatments (glatiramer
acetate, teriflunomide, or dimethyl fumarate). For isoelec-
tric focusing, we analyzed paired serum and CSF samples
from patients with MS from the Norwegian MS Registry
and Biobank at Haukeland University Hospital, and from
patients with Lyme neuroborreliosis from diagnostic bio-
banks at the Departments of Microbiology at Oslo Univer-
sity Hospital, Haukeland University Hospital, and
Sørlandet Hospital, Norway. Only G1m1/G1m3 heterozy-
gous individuals displaying IgG1 OCBs were included. MS
patients fulfilled the 2010 McDonald criteria, and neu-
roborreliosis patients met the criteria for definite Lyme
neuroborreliosis. The Regional Ethical Committee South
East approved the study (2009/23 S-04143a), and the
Regional Ethical Committee West approved the research
biobank at Haukeland University Hospital (046.03/
2010.1821). Written informed consent was obtained from
all participants before inclusion.
Flow cytometry
Mononuclear cells were isolated from CSF and blood as
previously described.10 The following fluorochrome-con-
jugated mouse anti-human antibodies from BD Bio-
sciences were used: CD3-BV510 (HIT3a), CD14-BV510
(MφP9), CD19-BV650 (SJ25C1), CD27-PE-CF594 (M-
T271), CD38-PerCP-Cy5.5 (HIT2), CD138-APC (MI15),
HLADR-APC-H7 (G46-6), IgG-PE-Cy7 (G18-145), and
Ki-67-PE (B56). In addition, we used antibodies against
IgG1 (4.0 lg/mL, HP6070, Thermo Fisher Scientific),
G1m1 (0.32 lg/mL, 10H1, Sanquin), and G1m3 (0.30 lg/
mL, SG-16, Sigma-Aldrich) conjugated with Alexa Fluor
680, Alexa Fluor 488, and Pacific Blue, respectively, using
antibody-labeling kits (Invitrogen, Molecular Probes).
Data were collected on an LSRFortessa cell analyzer (BD
Biosciences) equipped with 488-, 561-, 405-, and 640-nm
lasers, and analyzed using FlowJo version 10.2.
Isoelectric focusing and immunoblot
One of us (A.L.) randomized the patients and controls and
prepared paired samples of serum and CSF in new rela-
beled tubes. Researchers blinded to the diagnoses and the
group sizes performed the isoelectric focusing and
immunoblotting (A.TB.), and the interpretation of the
immunoblots (A.TB. and F.V.). All samples were diluted in
Milli-Q water to 25 mg/L, and the isoelectric focusing and
transferring to nitrocellulose membranes were performed
as previously described.11 After blocking in 2% milk, the
membrane was incubated overnight in mouse anti-human
antibodies against G1m3 (0.20 lg/mL, HP6027, Abingdon
Health), G1m1 (31 ng/mL, 10H1), or IgG1 (1.0 lg/mL,
HP6069, Invitrogen, Molecular Probes). After washing, the
membrane was incubated in a goat anti-mouse IgG anti-
body (Southern Biotec) at a 1:20,000 dilution for 1 h, and
visualized using SuperSignal West Pico (Thermo Fisher
Scientific) in a G:BOX digital camera system (Syngene).
Between the staining with anti-G1m3 and anti-G1m1 anti-
bodies, the membranes were stripped in Restore Western
Blot Stripping Buffer (Thermo Fisher Scientific).
Determining G1m allotypes using ELISA
The plates (Nunc, 436014; Thermo Fisher Scientific) were
coated with primary antibodies against G1m1 (1.5 lg/mL,
10H1) or G1m3 (1.0 lg/mL, HP6027) at 4°C. After wash-
ing, serum diluted 1:5,000 was incubated in duplicate
wells for 1 h. Finally, the plates were washed again and
incubated with alkaline phosphatase-conjugated goat anti-
human IgG (Sigma-Aldrich) for 1 h. The signal was
visualized with phosphatase substrate (Sigma-Aldrich)
reactivity measured at 405 nm.
Statistics
All statistical tests are given in the figure legends. The
level of significance was set at 5%, and all tests were two-
sided. The analyses were performed in JMP Pro 12 and
GraphPad Prism 6 for Mac OS X.
Results
In order to characterize the phenotypes and allotypes of
antibody-secreting cells (ASCs) in MS, we performed flow
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cytometry on mononuclear cells from blood and CSF
from 29 patients (Fig. 1A). The frequencies of B cells
were lower in CSF compared to blood, while the CSF
B-cell compartment was highly enriched for
CD19dimCD27hiCD38+ ASCs (median 14% [interquartile
range [IQR] 0–39%] in CSF vs. 1.6% [0.71–3.1%] in
blood; Fig. 1B). Furthermore, a vast majority of the ASCs
in the CSF expressed the IgG1 isotype (94% [79–100%];
Fig. 1B).
Remarkably, in G1m1/G1m3 heterozygous patients,
nearly all IgG1 ASCs in the CSF displayed the G1m1 allo-
type (median 99% [IQR 94–100%]; Fig. 2A and B). Fur-
ther characterization of the IgG1 ASCs showed that the
great majority expressed CD138 (90% [84–96%]) and
HLA-DR (82% [65–88%]), and virtually all expressed
high levels of the proliferation marker Ki-67 (100% [99–
100%]; Fig. 2C and D). This phenotype is compatible
with that of recently activated plasmablasts.12 By utilizing
an alternative gating strategy, we could not find any
CD19CD27+CD38+ IgG ASCs in the CSF (data not
shown). In contrast to the findings in the CSF, the G1m1
and G1m3 allotypes were evenly distributed among IgG1
ASCs B cells in the blood of G1m1/G1m3 heterozygous
patients, as expected from random allelic exclusion
(Fig. 2B).
We reasoned that the strong dominance of G1m1 posi-
tive B cells in CSF found by flow cytometry would also
be reflected in intrathecally synthesized IgG1. In order to
examine whether this phenomenon could also be
observed in a disease where the target antigen of the
intrathecal immune response has been defined, we deter-
mined the G1m allotypes in additional cohorts of patients
with MS and controls with Lyme neuroborreliosis by
serological typing using ELISA. We subsequently
compared paired samples of CSF and serum from G1m1/
G1m3 heterozygous patients with MS (n = 28) and con-
trols with Lyme neuroborreliosis (n = 16) by isoelectric
focusing and immunoblotting (Fig. 3A and B). A vast
majority of the MS patients displayed OCBs of the G1m1
allotype only (Fig. 3B). In contrast, close to all controls
had an intrathecal synthesis also of the G1m3 allotype
(Fig. 3B). The difference between the proportions of
patients and controls with an intrathecal synthesis of only
G1m1, only G1m3, or both allotypes was highly statisti-
cally significant (P < 0.0001).
Finally, to investigate whether the G1m1 allotype is
associated with a more severe disease course, we serologi-
cally determined the allotypes of an additional cohort of
MS patients and calculated the MS Severity Score (MSSS)
in our total patient population (n = 124). There were no
significant differences in MSSS between patients stratified
according to their G1m allele status (Fig. S1, P = 0.15).
Discussion
This is the first observation of a B-cell response in any
human or animal disease that is restricted to a certain
allotype variant. Importantly, the finding that G1m1 and
G1m3 are evenly distributed among OCBs in the CSF of
patients with neuroborreliosis suggests that the strong
selective enrichment of G1m1 positive B cells is uniquely
related to MS.
The mechanisms driving the B-cell response in MS are
not known. We and others have shown that the IgG-
producing B cells in CSF are somatically hypermutated
and have identical or clonally related counterparts in
blood,10,13 and it was recently shown that the maturation
of CNS B cells could be initiated in cervical lymph
Figure 1. The majority of the antibody-secreting cells in the cerebrospinal fluid (CSF) of MS patients express the IgG1 isotype. (A) After excluding
debris and doublets (not shown), mononuclear cells in blood and CSF were gated for the expression of CD19, C27, and CD38, and assayed for
the expression of IgG and IgG1. (B) The frequencies of B cells, of antibody-secreting cells among B cells, and of antibody-secreting cells expressing
IgG1 in blood and CSF are shown (n = 29, Wilcoxon signed-rank test). Results are presented as box plot diagrams with median, upper and lower
quartile, and minimum/maximum values.
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nodes.14 Although it is possible that the selection of B
cells carrying the G1m1 allotype occurs during the initia-
tion of the B-cell response in the periphery, the lack of
any allotype restriction in the blood could indicate a
selection at the blood–brain barrier or within the
intrathecal compartment. Moreover, the lack of
association between the G1m1 allotype and disease
course, and the finding of allotype restriction in patients
with different disease duration and MS subtype (progres-
sive and relapsing remitting), suggest that the mechanism
operates throughout the disease course and is not directly
linked to disease progression. Further characterization of
Figure 2. Antibody-secreting cells of the G1m1 allotype are selectively enriched in the cerebrospinal fluid (CSF) of G1m1/G1m3 heterozygous MS
patients, and the cells have a phenotype compatible with highly proliferating plasmablasts. (A) A representative flow cytometry experiment from a
G1m1/G1m3 heterozygous MS patient. The cells were gated for expression of IgG1 as shown in Fig. 1, and assayed for the expression of G1m1
and G1m3. (B) The frequencies of G1m1 and G1m3 antibody-secreting cells in the CSF of G1m1/G1m3 heterozygous patients (left panel), G1m1
homozygous patients (middle panel) and G1m3 homozygous (right panel) are shown. Double negative cells (in CSF median [range] 0% [0–3.8%]
and in blood 2.7% [1.4–7.2%]) were excluded when estimating the frequencies. Two G1m1/G1m3 heterozygous patients, two G1m1
homozygous patients, and five G1m3 homozygous patients had no detectable IgG1-secreting B cells in the CSF. Frequencies of G1m1- and
G1m3-expressing cells were compared between CSF and blood for G1m1/G1m3 heterozygous patients (n = 11 paired samples, Wilcoxon signed-
rank test). (C) Antibody-secreting cells (ASCs) were gated for the expression of CD19 and high levels of CD27, in addition to the expression of
CD38, IgG, and IgG1, while memory B cells were gated for the expression of CD19, intermediate levels of CD27, and absence of CD38. (D) The
frequencies of IgG1 ASCs and memory B cells expressing CD138, HLA-DR, and the proliferation marker Ki-67 (n = 20, Wilcoxon signed-rank test).
Positive gates were set using fluorescence minus one with isotype controls (FMO + iso). Results are presented as box plot diagrams with median,
upper and lower quartile, and minimum/maximum values.
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the IgG1 ASCs in the CSF of MS patients showed that
these cells express CD38, CD138, and HLA-DR, together
with dim levels of CD19 and high levels of CD27. This is
in line with the results of a previous study characterizing
intrathecal B cells,15 but contrasts another study that
demonstrated increased numbers of CD19–CD138+
plasma cells.16 Importantly, we show for the first time
that the intrathecal IgG1 ASCs express high levels of Ki-
67, suggesting that the cells are newly derived and prolif-
erate intrathecally.
The G1m1 and the G1m17 allotypes are in near perfect
linkage disequilibrium in Caucasians and are thus inher-
ited together on the same chromosome. Accordingly, the
mechanisms responsible for the selection of G1m1 plas-
mablasts could be connected to the G1m1 and/or the
G1m17 allotypes. It is possible that the allotypes interfere
with the Iga/Igb heterodimer of the B-cell receptor (BCR)
and influence receptor clustering and signaling, or that
they modulate the intracellular transport of the antigen–
antibody complexes and the subsequent antigen-presenta-
tion on HLA class II molecules. Another possibility is that
yet unidentified MS-associated polymorphisms in the
variable heavy chain (VH) region are inherited together
with the G1m polymorphisms. Alternatively, the G1m1
and/or G1m17 polymorphisms could indirectly cause
allosteric changes in the VH region influencing the bind-
ing affinity of the IgG1 BCR.17 Finally, it has been shown
that the G1m allotypes could affect the binding affinities
of soluble IgG1 for the neonatal Fc receptor (FcRn).18
The FcRn is indeed expressed at the blood–brain barrier
where it contributes to the efflux of IgG from the
CNS.19,20
A limitation of the present study is the lack of con-
trols with other inflammatory neurological diseases in
the flow cytometry experiments. However, such diseases
are rare, and only approximately 40% of them would
be G1m1/G1m3 heterozygous, out of whom only a pro-
portion would be expected to have a sufficient number
of plasmablasts in the CSF. Therefore, in order to
include a homogenous control group of a sufficient
size, we performed immunoblotting of isoelectric
focused paired samples of CSF and serum from patients
with Lyme neuroborreliosis determined to be G1m1/
G1m3 heterozygous and positive for oligoclonal bands
in the CSF.
In conclusion, our study indicates that the G1m allo-
types may have a fundamental influence on the
immune response in MS, and that the G1m1 allotype
could represent a new therapeutic target in a subset of
patients.
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Figure 3. The intrathecal IgG1 synthesis is dominated by the G1m1 allotype in G1m1/G1m3 heterozygous MS patients, but not in controls with
Lyme neuroborreliosis (NB). (A) A representative isoelectric focusing experiment with paired serum and cerebrospinal fluid (CSF) samples from two
G1m1/G1m3 heterozygous MS patients and a heterozygous control with NB. CSF samples from a G1m1 homozygous and a G1m3 homozygous
MS patient were included as control samples. Intrathecal synthesis was determined as the presence of two or more bands exclusive to CSF or at
least two times stronger than corresponding bands in serum. (B) Isoelectric focusing with immunoblotting was performed on G1m1/G1m3
heterozygous patients with MS (n = 28) and controls with NB (n = 16). The numbers of patients versus controls with IgG1 OCBs using only
G1m1, only G1m3 or both were compared using Fischer’s exact test for a 2 9 3 table.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1: G1m allotypes are not associated with the dis-
ease severity in MS. The MS severity score (MSSS) was
estimated for G1m3 homozygous patients (n = 50),
G1m1/G1m3 heterozygous patients (n = 58), and G1m1
homozygous patients (n = 18). Bars depict mean  SD,
and differences between the three groups were tested
using Kruskal–Wallis test.
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